Tercica

Sector:
Healthcare

Location:
Brisbane, CA

Year Funded:
2003

Status:
IPO/Acquired by Ipsen

Website:
www.tercica.com


Summary:
Tercica is a late-stage biopharmaceutical company focused on the development and commercialization of therapies to treat endocrine disorders, including human growth and diabetes. Tercica‚Äôs lead product is Increlex®, which is a long-term replacement therapy for the treatment of short stature in children with severe primary insulin-like growth factor-1 deficiency, or severe Primary IGFD, and for children with growth hormone gene deletion who have developed neutralizing antibodies to growth hormone.

 Tercica Case Study